Unger Marcus M, Spiegel Jörg, Dillmann Klaus-Ulrich, Grundmann David, Philippeit Hannah, Bürmann Jan, Faßbender Klaus, Schwiertz Andreas, Schäfer Karl-Herbert
Department of Neurology, Saarland University, Kirrberger Strasse, 66421, Homburg, Saar, Germany.
Department of Neurology, Saarland University, Kirrberger Strasse, 66421, Homburg, Saar, Germany.
Parkinsonism Relat Disord. 2016 Nov;32:66-72. doi: 10.1016/j.parkreldis.2016.08.019. Epub 2016 Aug 26.
Patients with Parkinson's disease (PD) frequently have gastrointestinal symptoms (e.g. constipation) and exhibit the PD-typical pathohistology in the enteric nervous system (ENS). Both, clinical symptoms and pathohistological changes in the ENS occur at early stages and can precede the motor manifestations of PD. Two recent studies reported an association between changes in gut microbiota composition and PD. We hypothesized that alterations in gut microbiota might be accompanied by altered concentrations of short chain fatty acids (SCFA), one main metabolic product of gut bacteria.
We quantitatively analyzed SCFA concentrations (using gas chromatography) and microbiota composition (using quantitative PCR) in fecal samples of 34 PD patients and 34 age-matched controls.
Fecal SCFA concentrations were significantly reduced in PD patients compared to controls. The bacterial phylum Bacteroidetes and the bacterial family Prevotellaceae were reduced, Enterobacteriaceae were more abundant in fecal samples from PD patients compared to matched controls.
Our study confirms the recently reported association between PD and the abundance of certain gut microbiota and shows a reduction in fecal SCFA concentrations (one main metabolic product of certain gut bacteria). The reduction in SCFA might, theoretically, induce alterations in the ENS and contribute to gastrointestinal dysmotility in PD. Prospective longitudinal studies in subjects at risk for PD are required to further elucidate the causal role of gut microbiota and microbial products in the development of PD and PD-associated dysmotility.
帕金森病(PD)患者常有胃肠道症状(如便秘),且在肠道神经系统(ENS)中表现出PD典型的病理组织学特征。ENS的临床症状和病理组织学变化均出现在疾病早期,且可先于PD的运动症状出现。最近两项研究报道了肠道微生物群组成变化与PD之间的关联。我们推测肠道微生物群的改变可能伴随着短链脂肪酸(SCFA)浓度的变化,SCFA是肠道细菌的一种主要代谢产物。
我们对34例PD患者和34例年龄匹配的对照者的粪便样本中的SCFA浓度(采用气相色谱法)和微生物群组成(采用定量PCR法)进行了定量分析。
与对照组相比,PD患者粪便中的SCFA浓度显著降低。与匹配的对照组相比,PD患者粪便样本中拟杆菌门和普雷沃氏菌科减少,肠杆菌科更为丰富。
我们的研究证实了最近报道的PD与某些肠道微生物群丰度之间的关联,并表明粪便中SCFA浓度(某些肠道细菌的一种主要代谢产物)降低。理论上,SCFA的降低可能会引起ENS的改变,并导致PD患者出现胃肠动力障碍。需要对有PD风险的受试者进行前瞻性纵向研究,以进一步阐明肠道微生物群和微生物产物在PD发生发展及相关胃肠动力障碍中的因果作用。